Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2019-03-12 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Placement to Accelerate Development of ATL1102 in DMD 2 pages 110.7KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 13 March 2019 from Antisense Therapeutics Limited regarding a placement to raise capital for accelerating development of ATL1102 in Duchenne Muscular Dystrophy (DMD). It details the placement size, share issue price, use of funds, and ongoing clinical trials. The document focuses on fundraising and capital raising activities, including the appointment of a lead manager and backing by institutional shareholders. There is no detailed financial report, earnings data, or comprehensive financial statements. The content is consistent with a capital/financing update rather than an annual report, earnings release, or other report types. The document length (8824 characters) is sufficient to be more than a brief announcement but the content clearly centers on capital raising and development funding. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-03-12 English
Pause in trading 1 page 112.2KB
Regulatory Filings Classification · 95% confidence The document is a short market release announcing a temporary pause in trading of the company's securities. It is dated and signed by an ASX Listings Compliance officer. There is no financial data, no report attached or referenced beyond the trading pause notice. The document is an official regulatory announcement related to trading status, fitting best under Regulatory Filings (RNS) as it does not match any other specific category such as financial reports, management changes, or capital updates.
2019-03-10 English
Trading Halt 2 pages 647.1KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Antisense Therapeutics Limited regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement related to a placement to accelerate development. The document is short (2153 characters) and does not contain financial data, results, or detailed report content. It is an official notice about a trading halt, which is a regulatory announcement rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-03-10 English
Half Yearly Report and Accounts 25 pages 578.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Antisense Therapeutics Limited Appendix 4D For the Half-year ended 31 December 2018' and contains detailed financial results, directors' report, auditor's review report, and comprehensive financial statements for the half-year period ending 31 December 2018. It includes profit and loss statements, balance sheets, cash flow statements, notes to financial statements, and directors' declarations. The document also discusses operational reviews and clinical trial updates, which are typical in interim or quarterly reports. The presence of an auditor's review report and detailed financial data confirms this is a substantive financial report for a period shorter than a full fiscal year. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-02-26 English
Appendix 4C - quarterly 5 pages 210.1KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed quarterly financial data including consolidated statement of cash flows, cash flow from operating, investing, and financing activities, reconciliation of cash and cash equivalents, payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document covers a quarter ended 31 December 2018 and includes substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement or a certification, but a full quarterly financial report. Therefore, the correct classification is IR with high confidence. Q2 2019
2019-01-29 English
Updated Company Presentation 15 pages 3.9MB
Investor Presentation Classification · 95% confidence The document is a detailed company presentation focusing on the company's clinical pipeline, therapeutic programs, and strategic outlook. It includes forward-looking statements, corporate snapshot, scientific advisory board details, clinical trial status, and product development updates. There are no financial statements, regulatory certifications, or voting results. The content is typical of an investor presentation aimed at providing comprehensive information about the company's business, clinical progress, and value creation potential to investors. The length (15,000 characters) and detailed content confirm it is not a brief announcement or a simple report publication notice. Therefore, the document best fits the category of an Investor Presentation (IP).
2019-01-22 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.